Opportunities for acquiring external assets may move faster than an internal BD group can react. Inova supports a capability to be both fast and nimble in the hunt for novel assets from scouting through to licensing and beyond to alliance management. Read more »
The chairmen of Johnson & Johnson Pharmaceuticals and GlaxoSmithKline R&D announced a trailblazing venture fund for fast-tracking early stage assets during the closing plenary session at BIO-Europe Spring® in Amsterdam. Read more »
The biotech sector continues to outperform other industries in public equity markets in the United States, but private equity is more selective about opportunities, according to Biotechnology Industry Organization (BIO). Read more »
Lead executives with four of the headline-grabbing deals of the past year shared insights into the negotiation with participants at BIO-Europe Spring® in Amsterdam. Read more »
The Catalonia biotech sector has developed rapidly in the two years since BIO-Europe Spring® last visited Barcelona. Major infrastructure has come online, and companies in a start-up phase have now matured in asset development and are ready to partner internationally. Read more »
Recent successes for biotech assets emerging from clusters of start-ups demonstrate the strength of this approach for building companies from start-up to launch. Read more »
With venture capital moving into orphan drugs, can big pharma be far behind? During the opening session at BIO-Europe Spring® both the keynote speaker and a panel of senior executives described the promise and the pitfalls in this broad market where success is built niche-by-niche. Read more »
High level panel discussions on dealmaking were brought back to earth by a single question from the audience in two different sessions at BIO-Europe Spring®: “How do you value a deal?” Read more »
Hot Companies
Newsletter